
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated robust growth in its transcatheter aortic valve replacement (TAVR) segment, with revenue increasing by 10.6% year-over-year, leading to an upward revision of its 2025 growth guidance to 7-8%. The company has also shown impressive performance in its transcatheter mitral and tricuspid valve technologies (TMTT), reporting a remarkable year-over-year growth of 53.2%, driven by strong demand for products like PASCAL and EVOQUE. With confidence in sustaining revenue growth above 10% through 2026 and an increased EPS outlook for FY25, Edwards Lifesciences positions itself favorably for continued success in the evolving medical device market.
Bears say
Key risks contributing to a negative outlook on Edwards Lifesciences's stock include uncertainties surrounding the growth trajectory of the transcatheter aortic valve replacement (TAVR) market and the potential for a smaller total addressable market than currently expected. Additionally, delays in product innovations within the minimally invasive tricuspid and mitral valve segments may hinder the company's sales growth, while emerging competition could pressure market share and pricing. Finally, a challenging global regulatory and reimbursement landscape poses further risks by potentially delaying technology adoption and impacting revenue growth forecasts.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares